prev_day,curr_day,ticker,Shs Float,Inst Own,Insider Own,market_cap,Short Float,ATR,PDC Range %,total_range_percent,premarket_range_percent,gap_percent,Cash In Hand,Cash Need,DT Overall Risk,DT Offering Ability,DT Amount Excluding Shelf,DT Historical,Daily FT %,PM FT %,First Hour FT %,v,Premarket Volume (cumm),First Hour Volume,Daily Volume Forecast,Highest Volume,Highest Volume Time - num_trans,Aggregated Volume Before Highest Volume,Highest Bar Volume Ratio %,c,h,l,o,vw,Target 0%,Target 25%,Target 50%,Target 75%,Target 100%,Premarket High,Premarket Low,Premarket High Time,Premarket Low Time,Regular Market High Time,Regular Market Low Time,Highest Volume Time,name,primary_exchange,list_date,type,share_class_shares_outstanding,keywords,publishers,titles,pp,r4,r5,r6,s4,s5,s6
2023-01-24,2023-01-25,ATNF,1.41M,15.30%,0.70%,13.53M,36.98%,1.11,68.77,61.14,36.62,15.77,,High,High,High,High,High,1698.27,146.76,175.89,23.95M,2.07M,2.48M,20.69M,698.8K,2099,13.56M,5.15,4.24,5.35,3.32,3.67,4.4351,1,1,1,0,0,4.29,3.14,19:24:00,15:20:00,00:26:00,20:24:00,00:24:00,180 Life Sciences Corp. Common Stock,XNAS,2017-06-27,CS,2.24M,,GlobeNewswire,180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease,3.23,3.31,3.39,3.42,3.03,2.95,2.92
